BGM Group Chairman and Co-CEO Steps Down; Father Assumes Chair, New Co-CEO Appointed
BGM is trading near its 52-week low of $0.25 (8.7% above the low) on light trading volume (0.1× avg).
Summary
BGM Group's Chairman and Co-CEO Chen Xin has resigned, with his father stepping in as Chairman and a new Co-CEO taking the reins. The leadership change unfolds against a backdrop of financial distress and recent governance upheaval.
Key Events · Executive and Board Changes · BGM
-
Chairman/Co-CEO Resigns
Effective July 30, 2026, Chen Xin resigned as Chairman and Co-CEO, citing personal reasons.
-
Father Appointed Chairman
Stepping into the Chairman role is Zhanchang Xin, father of the outgoing chairman, who brings extensive pharmaceutical industry experience.
-
New Co-CEO Named
Hong Li, currently CFO of a subsidiary, was appointed Co-CEO. She brings 35 years of financial management experience to the position.
-
Governance Concerns
The father-son succession, set against recent board upheaval and financial distress, raises governance red flags.
Analysis · BGM · Life Sciences
Citing personal reasons, Chairman and Co-CEO Chen Xin resigned. The board moved swiftly, naming his father, Zhanchang Xin, as Chairman and Hong Li as Co-CEO. The shake-up arrives after a turbulent stretch: a board overhaul in May, a deeply dilutive $12M placement, a reverse split authorization, and a $19.9M net loss accompanied by material weaknesses. The father-son succession inevitably raises governance questions, particularly given the company's fragile condition.
At the time of this filing, BGM was trading at $0.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $114.3M. The 52-week trading range was $0.25 to $11.80. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.